統合失調症における認知機能障害および陰性症状に対するペルゴリドの効果的な補助療法

基本情報

NCT ID

NCT00197483

ステータス

一時中断

試験のフェーズ

-

試験タイプ

観察

目標被験者数

20

治験依頼者名

Hamamatsu University

概要

Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)